论文信息 - A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas - 字舞流文

A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas

H. Tun | D. Brander | S. Schuster | A. Mato | Wei He | F. Foss | I. Isufi | B. Anderson | L. Roeker | S. Huntington | A. Sitlinger | K. Kennard | W. Ding | A. Rosenthal | A. Koehler | M. A. Moustafa | A. Kearney | C. King | Casey N. Aitken | Min Gui